FORT WORTH, Texas--(BUSINESS WIRE)--May 21, 2006--Alcon, Inc. (NYSE:ACL) announced today that the Centers for Medicare and Medicaid Services (CMS) recognized the AcrySof(R) IQ intraocular lens (IOL) ...
PanOptix is already one of the leading presbyopia-correcting IOLs in more than 70 countries. It is designed for today’s active lifestyles, from viewing mobile devices and computer screens to ...
PanOptix, the first and only advanced trifocal lens for U.S. patients undergoing cataract surgery, will be showcased in educational events and clinical data presentations First-ever analyses on IOLs ...
TORONTO, Nov. 17, 2020 /CNW/ - Alcon, the global leader in eye care, is pleased to announce the Canadian launch of AcrySof ® IQ Vivity ®, a first-of-its-kind, surgical lens designed to help cataract ...
The FINANCIAL — Basel, June 18, 2018 Alcon, the global leader in eye care and a division of Novartis, unveils new data showing significantly improved near and intermediate distance vision with the ...
Basel, Switzerland, July 1, 2015 – Alcon, the global leader in eye care and a division of Novartis, has received European CE Mark for its AcrySof® IQ Aspheric IOL with the UltraSert™ Pre-loaded ...
Please provide your email address to receive an email when new articles are posted on . A prospective comparative case series of 50 patients implanted bilaterally ...
Please provide your email address to receive an email when new articles are posted on . Alcon’s AcrySof IQ monofocal IOL and AcrySof IQ PanOptix trifocal IOL both had positive results in studies ...
MIDDLETOWN, Ky., Sept. 26, 2019 /PRNewswire-PRWeb/ -- Frank Burns, MD, the medical director of Middletown Eye Center was one of the first surgeons in Kentucky to implant the Alcon Acrysof IQ PanOptix ...
Here is the current list (as of Feb. 9, 2011) of posterior chamber (P-C) and anterior chamber (A-C) intraocular lenses recognized by CMS. – Crystalens, manufactured by Eyeonics (now Bausch & Lomb). – ...
PanOptix delivers an exceptional combination of near, intermediate and distance vision and substantially reduces the need for glasses 1,2 More than ninety-nine percent of PanOptix patients in the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results